eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2022
vol. 24
 
Share:
Share:
Review paper

Prophylactic vaccinations management in patients undergoing allergen immunotherapy – a review

Ewa Czerwińska
1
,
Marita Nittner-Marszalska
2
,
Agnieszka Mastalerz-Migas
3
,
Leszek Szenborn
1

1.
Clinical Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland
2.
Clinical Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, Wroclaw, Poland
3.
Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland
Family Medicine & Primary Care Review 2022; 24(2): 163–167
Online publish date: 2022/06/30
Get citation
 
PlumX metrics:
 
1. Pawankar R, Canonica G, Holgate S, et al, eds. WAO white Book on Allergy. Available from URL: https://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf.
2. The European Academy of Allergy and Clinical Immunology. EAACI Advocacy Manifesto Tackling the Allergy Crisis in Europe – Concerted Policy Action Needed. 2015. Available from URL: https://www.veroval.info/-/media/diagnostics/files/knowledge/eaaci_advocacy_manifesto.pdf.
3. Stuck BA, Czajkowski J, Hagner AE, et al. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol 2004; 113(4): 663–668.
4. Chung JH, Han CH. Health related quality of life in relation to asthma – data from a cross sectional study. J Asthma 2018; 55(9): 1011–1017.
5. Warren CM, Jiang J, Gupta RS. Epidemiology and Burden of Food Allergy. Curr Allergy Asthma Rep 2020; 20(6): 1–14.
6. Valenta R, Campana R, Marth K, et al. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012; 272(2): 144–157.
7. COVID Live. Coronavirus Statistics. Worldometer 2022 [cited: 14.03.2022]. Available from URL: https://www.worldometers.info/coronavirus/.
8. Kaye AD, Okeagu CN, Pham AD, et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. Best Pract Res Clin Anaesthesiol 2021; 35(3): 293–306.
9. Sallusto F, Lanzavecchia A, Araki K, et al. From Vaccines to Memory and Back. Immunity 2010; 33(4): 451–463.
10. Muńoz Carrillo JL, Castro García FP, Coronado OG, et al. Physiology and Pathology of Innate Immune Response Against Pathogens. In: Rezaei N, ed. Physiology and Pathology of Immunology. 2017, doi: 10.5772/intechopen.70556.
11. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010; 125(2): S3–S23.
12. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015; 16(4): 343–353.
13. Marshall JS, Warrington R, Watson W, et al. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol 2018; 14(49): 1–10, doi: 10.1186/s13223-018-0278-1.
14. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327(5963): 291–295.
15. Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. Biomed Res Int 2021; 2021: 1157023, doi: 10.1155/2021/1157023.
16. Behzadi P, García-Perdomo HA, Karpiski TM. Toll-Like Receptors: General Molecular and Structural Biology. J Immunol Res 2021; 2021: 9914854, doi: 10.1155/2021/9914854.
17. Perera Molligoda Arachchige AS. Human NK cells: From development to effector functions. Innate Immun 2021; 27(3): 212–229.
18. Pfefferle A, Jacobs B, Haroun-Izquierdo A, et al. Deciphering Natural Killer Cell Homeostasis. Front Immunol 2020; 11: 1–11.
19. Fujita H, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy 2012; 2(2), doi: 10.1186/2045-7022-2-2.
20. Ozdemir C, Kucuksezer UC, Akdis M, et al. Mechanisms of immunotherapy to wasp and bee venom. Clin Exp Allergy 2011; 41: 1226–1234.
21. Bali P, Rafi A. Immunological mechanisms of vaccination. Nat Immunol 2011; 12(6): 509–517.
22. Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: immunological mechanism and beyond. Vaccines 2021; 9(2): 1–20.
23. Elkashif A, Alhashimi M, Sayedahmed EE, et al. Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. Clin Transl Immunol 2021; 10(10): e1345, doi: 10.1002/cti2.1345.
24. Chang J. Adenovirus vectors: excellent tools for vaccine development. Immune Netw 2021; 21(1): e6, doi: 10.4110/in.2021.21.e6.
25. Manohar A, Ahuja J, Crane JK. Immunotherapy for Infectious Diseases: Past, Present, and Future. Immunol Invest 2015; 44(8): 731–737.
26. Plotkin SA. Correlates of Protection Induced by Vaccination. Clin Vaccine Immunol 2010; 17(7): 1055–1065.
27. Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol 2020; 31(S25): 1–101.
28. Shamji MH, Sharif H, Layhadi JA, et al. Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma. J Allergy Clin Immunol 2022; 149(3): 791–801.
29. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011; 66: 725–732.
30. Pitsios C, Demoly P, Bilň MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy Eur J Allergy Clin Immunol 2015; 70(8): 897–909.
31. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127(1): S1–S55, doi: 10.1016/j.jaci.2010.09.034.
32. Sturm GJ, Varga E-M, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018; 73: 744–764.
33. Calderon MA, Demoly P, Gerth van Wijk R, et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012; 2(1): 20, doi: 10.1186/2045-7022-2-20.
34. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61(s82): 1–10.
35. Komunikat Gównego Inspektora Sanitarnego z dnia 28 padziernika 2021 r. w sprawie Programu Szczepie Ochronnych na rok 2022. Available from URL: http://dziennikmz.mz.gov.pl/DUM_MZ/2021/85/akt.pdf (in Polish).
36. European Centre for Disease Prevention and Control. Italy: Recommended vaccinations. Vaccine Scheduler. ECDC. 2021. Available from URL: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=103&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=false.
37. European Centre for Disease Prevention and Control. Austria: Recommended vaccinations. Vaccine Scheduler. ECDC. 2021. Available from URL: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=18&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=false.
38. UK Health Security Agency. The routine immunisation schedule. 2022. Available from URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1055877/UKHSA-12155-routine-complete-immunisation-schedule_Feb2022.pdf.
39. Ullrich D, Ullrich K, Mussler S, et al. Vaccination during concurrent subcutaneous immunotherapy: safety of simultaneous application. Eur Ann Allergy Clin Immunol 2015; 47(1): 10–14.
40. Czerwiska E, Nittner-Marszalska M, Pawowicz R, et al. Simultaneous influenza vaccination and hymenoptera venom immunotherapy is safe. Vaccines 2021; 9(4): 1–9.
41. Masieri S, Bachert C, Ojeda P, et al. Allergen Immunotherapy management during vaccinations: an international survey. World Allergy Organ J 2021; 14(11): 100601.
42. Garner-Spitzer E, Seidl-Friedrich C, Zwazl I, et al. Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias. Vaccine 2018; 36(20): 2816–2824.
43. Czerwiska E, Nittner-Marszalska M, Zaryczaski J, et al. Influenza and Other Prophylactic Vaccination Coverage in Polish Adult Patients Undergoing Allergen Immunotherapy – A Survey Study among Patients and Physicians. Vaccines 2022; 10(4): 576, doi: 10.3390/vaccines10040576.
44. Jutel M, Torres MJ, Palomares O, et al. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals – EAACI recommendations. Allergy 2022, doi: 10.1111/all.15252. Online ahead of print.
45. Kruszewski J, Cichocka-Jarosz E, Czarnobilska E, et al. Rekomendacje Polskiego Towarzystwa Alergologicznego dotyczce kwalifikacji osób z alergi i anafilaksj do szczepienia przeciw COVID-19. Alergol Pol 2021; 8(1): 1–8 (in Polish).
Copyright: © 2022 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.